Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,735.00
Bid: 1,735.00
Ask: 1,735.50
Change: 6.50 (0.38%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,736.50
Low: 1,729.00
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sunday newspaper round-up: Meggitt, GlaxoSmithKline, Luxury goods

Sun, 15th Aug 2021 17:08

(Sharecast News) - Ministers must be prepared to block a takeover of Meggitt if any bidder tries to buy it without giving binding commitments on investment and jobs, the FTSE 250 aerospace and defence manufacturer's chairman warned this weekend. Sir Nigel Rudd said that while "clearly, price is important", any new owner would need to give Meggitt and the government undertakings, including to keep the company's headquarters in Coventry and maintain R&D spending. - Sunday Times

A legal battle between Britain's two pharma champions has escalated after Glaxo Smith Kline launched a counter-claim against rival Astra Zeneca. It revolves around sales of Glaxo's top-selling cancer drug, Zejula, a treatment for ovarian and other cancers. Astra licenses the underlying technology to Glaxo, and claims it should receive a greater share of Zejula's sales. It accused Glaxo of breaching the terms of its agreement and has hired accountants KPMG to audit Zejula's sales. A source suggested the claim could reach hundreds of millions of pounds. - Sunday Times

The fortunes of the world's biggest luxury goods groups have been lifted by a splurge on expensive jewellery, watches, fashion and champagne as billions in spare cash is spent on big-budget treats. Sales at 11 of the largest luxury groups and their brands have grown by a fifth on average compared with 2019, before the pandemic began. And they have more than doubled on last year. - Financial Mail on Sunday

Talks to get the US investment giant Apollo on board to finance a bid to buy Morrisons have cooled after a shock increase in the offer price earlier this month. New York-based Apollo had been lined up to join a takeover consortium led by the private equity firm Fortress. But market sources this weekend said they believed Apollo had baulked at the dramatic £400 million price increase for the supermarket chain. - Financial Mail on Sunday

The magazine publisher behind The Week is on the verge of being sold to Future, the FTSE 250- listed media group. Future, which also owns Marie Claire and football magazine FourFourTwo, is in 'advanced' discussions with the private equity owners of Dennis Publishing about a takeover of a large number of the company's most well-known publications. - Financial Mail on Sunday

Imposing "premature austerity" again will undermine the fight against climate change and stop poorer households going green, one of the world's leading climate economists has warned the government, amid claims that the Treasury is resisting policies to tackle the crisis. Nicholas Stern, the author of the seminal 2006 government study into the costs of climate change, said comprehensive programmes were needed to help poorer households make the switch to electric cars and away from gas heating, if the government hoped to bring all greenhouse gas emissions to net zero by 2050. - Guardian

BT is threatening to crush competition and slow Britain's upgrade to faster full-fibre broadband by bringing in unfair prices, Virgin Media O2 has warned. The newly merged telecoms giant claims discounts being offered to broadband retailers buying access to the new network set a "dangerous precedent" that will scupper investment. - Sunday Telegraph

Amazon is adding own-brand groceries to its UK website to bolster its online offering, as the retail titan steps up its assault on British supermarkets. The business will allow shoppers to add hundreds of "By Amazon" and "Our Selection" products to their virtual baskets in the coming weeks. Bosses are expected to launch an advertising blitz to promote the ranges as they seek to attract more customers to its Fresh service, sources said. - Sunday Telegraph

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.